New Horizons – Understanding the Concept of “Precision Oncology”
Understanding the Concept of "Precision Oncology" in patient-friendly language presented by Dr. Jason Sicklick of Moores Cancer Center UCSD at New Horizons 2019.
Understanding the Concept of "Precision Oncology" in patient-friendly language presented by Dr. Jason Sicklick of Moores Cancer Center UCSD at New Horizons 2019.
Want to know more about GIST? Do you have some burning questions to ask GIST experts? Members of the LRG GIST Global Expert Surveillance Team will be at the LRG offices on May 8th at 1:00 pm [...]
State of GIST: A Clinical Panel of Experts Presented by Jason Sicklick, MD, Moores Cancer Center, University of California, San Diego; and the GIST Experts Panel - Markku Martti Miettinen, MD, National [...]
Dr. Jason Sicklick and Norman Scherzer co-present poster at 2017 CTOS meeting. Norman Scherzer, Executive Director of The Life Raft Group, recently co-presented a poster at the 2017 CTOS (Connective Tissue Oncology [...]
The Life Raft Group and UCSD hosted a three-day event at University of California, San Diego UCSD-Moores Cancer Center from July 13th through July 15th. A GIST Awareness Day (GAD) event took place on July [...]
PICTURED: Dr. Jason Sicklick, Deb Melikian,Norman Scherzer, & Malcolm Aste Record numbers attended our GIST Day of Learning on July 15th in La Jolla, California. Over 100 people gathered to [...]
It's not too late to sign up for the GIST Day of Learning (GDOL) in La Jolla/San Diego on July 15th. We are very excited to have some of the top GIST experts present [...]
The Life Raft Group presented an informative webcast on Gene Fusions. Presented on February 22, 2017 Learn about: Recently identified gene fusions in GIST Populations they target Current studies that may identify them How they [...]
Jason Sicklick, M.D Recent findings from a population-based retrospective cohort study at the at Moores Cancer Center at UC San Diego Health, led by senior author, Jason Sicklick, M.D., indicate that small [...]
A recent study published in the Journal of Translational Medicine, presents important research findings for the 10-15% of GIST patients who lack mutations in KIT, PDGFRA, SDHX or RAS pathway indicators, the primary oncogenic [...]